Chinese Journal of Antituberculosis ›› 2024, Vol. 46 ›› Issue (9): 1069-1076.doi: 10.19982/j.issn.1000-6621.20240179
• Original Articles • Previous Articles Next Articles
Wang Fei1, Hua Duo1, Guo Jianjian1, Liu Chang1, Han Lu2(), Ren Yi1(
)
Received:
2024-05-09
Online:
2024-09-10
Published:
2024-08-30
Contact:
Han Lu, Email: CLC Number:
Wang Fei, Hua Duo, Guo Jianjian, Liu Chang, Han Lu, Ren Yi. Characteristic analysis of non-tuberculous mycobacterial pulmonary disease patients in Wuhan area from 2021 to 2023[J]. Chinese Journal of Antituberculosis, 2024, 46(9): 1069-1076. doi: 10.19982/j.issn.1000-6621.20240179
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.zgflzz.cn/EN/10.19982/j.issn.1000-6621.20240179
性别 年龄 | 患者[例(构成 比,%)] | 菌种分类[株(构成比,%)] | ||||
---|---|---|---|---|---|---|
胞内分枝杆菌 (332株) | 脓肿分枝杆菌 (115株) | 堪萨斯分枝杆菌 (35株) | 鸟分枝杆菌 (34株) | 其他 (9株) | ||
女性 | 297(58.24) | 183(59.41) | 87(28.25) | 6(1.95) | 28(9.08) | 4(1.30) |
15~34岁 | 5(1.68) | 1(1/5) | 2(2/5) | 1(1/5) | 1(1/5) | 0(0/1) |
35~44岁 | 14(4.71) | 7(50.00) | 3(21.43) | 0(0.00) | 4(28.57) | 0(0.00) |
45~54岁 | 70(23.57) | 39(54.92) | 26(36.62) | 2(2.82) | 3(4.23) | 1(1.41) |
55~64岁 | 84(28.28) | 51(57.30) | 24(26.97) | 1(1.12) | 11(12.36) | 2(2.25) |
65~74岁 | 100(33.67) | 65(63.11) | 28(27.18) | 1(0.97) | 9(8.74) | 0(0.00) |
>74岁 | 24(8.09) | 20(76.92) | 4(15.38) | 1(3.85) | 0(0.00) | 1(3.85) |
男性 | 213(41.76) | 149(68.66) | 28(12.90) | 29(13.36) | 6(2.77) | 5(2.31) |
15~34岁 | 8(3.76) | 2(2/8) | 0(0/8) | 3(3/8) | 1(1/8) | 2(2/8) |
35~44岁 | 10(4.69) | 6(60.00) | 0(0.00) | 4(40.00) | 0(0.00) | 0(0.00) |
45~54岁 | 22(10.32) | 12(54.54) | 2(9.09) | 7(31.82) | 1(4.55) | 0(0.00) |
55~64岁 | 64(30.05) | 42(65.63) | 10(15.63) | 10(15.62) | 0(0.00) | 2(3.12) |
65~74岁 | 67(31.46) | 53(74.64) | 12(16.90) | 3(4.23) | 3(4.23) | 0(0.00) |
>74岁 | 42(19.72) | 34(80.96) | 4(9.52) | 2(4.76) | 1(2.38) | 1(2.38) |
临床特征 | 胞内组(332例) | 脓肿组(115例) | 堪萨斯组(35例) | 统计检验值 | P值 |
---|---|---|---|---|---|
性别[例(构成比,%)] | χ2=39.534 | <0.001 | |||
女性 | 183(55.12) | 87(75.65) | 6(17.14) | ||
男性 | 149(44.88) | 28(24.35) | 29(82.86) | ||
年龄(岁,$\bar{x} \pm s$) | 63.60±10.67 | 60.60±10.26 | 53.30±13.20 | F=15.724 | <0.001 |
体质量指数($\bar{x} \pm s$) | 18.90±2.95 | 19.20±3.38 | 18.40±3.16 | F=0.762 | 0.467 |
吸烟[例(构成比,%)] | χ2=15.623 | <0.001 | |||
是 | 77(23.19) | 14(12.17) | 15(42.86) | ||
否 | 255(76.81) | 101(87.83) | 20(57.14) | ||
饮酒[例(构成比,%)] | χ2=10.079 | 0.006 | |||
是 | 35(10.54) | 5(4.35) | 8(22.86) | ||
否 | 297(89.46) | 110(95.65) | 279(77.14) | ||
结核病史[例(构成比,%)] | χ2=0.341 | 0.843 | |||
有 | 113(34.04) | 36(31.30) | 11(31.43) | ||
否 | 219(65.96) | 79(68.70) | 24(68.57) | ||
症状[例(发生率,%)] | |||||
咳嗽 | 240(72.29) | 83(72.17) | 27(77.14) | χ2=0.390 | 0.823 |
咳痰 | 161(48.49) | 67(58.26) | 20(57.14) | χ2=3.751 | 0.153 |
咯血 | 84(25.30) | 39(33.91) | 8(22.86) | χ2=3.557 | 0.169 |
发热 | 49(14.76) | 17(14.78) | 3(8.57) | χ2=1.015 | 0.602 |
胸痛 | 21(6.33) | 5(4.35) | 1(2.86) | χ2=1.288 | 0.525 |
盗汗 | 2(0.60) | 2(1.74) | 0(0.00) | χ2=0.142 | 0.706 |
呼吸困难 | 4(1.20) | 0(0.00) | 1(2.86) | χ2=0.003 | 0.953 |
影像学表现[例(发生率,%)] | |||||
斑片影 | 205(61.75) | 77(66.96) | 18(51.43) | χ2=2.864 | 0.239 |
结节影 | 216(65.06) | 79(68.70) | 22(62.86) | χ2=0.643 | 0.725 |
支气管扩张影 | 260(78.31) | 104(90.43) | 19(54.29) | χ2=22.345 | <0.001 |
空洞影 | 142(42.77) | 34(29.57) | 24(68.57) | χ2=17.534 | <0.001 |
胸膜增厚 | 102(30.72) | 34(29.57) | 11(31.43) | χ2=0.054 | 0.973 |
基础疾病[例(发病率,%)] | |||||
糖尿病 | 18(5.42) | 3(2.61) | 1(2.86) | χ2=1.986 | 0.371 |
高胆固醇血症 | 36(10.84) | 13(11.30) | 0(0.00) | χ2=4.291 | 0.117 |
高血压 | 46(13.86) | 10(8.70) | 3(8.57) | χ2=2.738 | 0.254 |
乙型病毒性肝炎 | 36(10.84) | 16(13.91) | 4(11.43) | χ2=0.758 | 0.684 |
贫血 | 90(27.11) | 26(22.61) | 5(14.29) | χ2=3.269 | 0.195 |
低蛋白血症 | 92(27.71) | 23(20.00) | 12(34.29) | χ2=3.842 | 0.146 |
胃食管反流 | 6(1.81) | 2(1.74) | 0(0.00) | χ2=0.381 | 0.537 |
自身免疫性疾病 | 5(1.51) | 0(0.00) | 0(0.00) | - | - |
合并肺部疾病[例(发病率,%)] | |||||
肺气肿、肺大疱 | 64(19.28) | 16(13.91) | 10(28.57) | χ2=4.054 | 0.132 |
慢性阻塞性肺疾病 | 62(18.67) | 18(15.65) | 13(37.14) | χ2=8.222 | 0.016 |
肺纤维化 | 2(0.60) | 0(0.00) | 0(0.00) | - | - |
毁损肺 | 21(6.33) | 4(3.48) | 2(5.71) | χ2=1.443 | 0.846 |
肺部肿瘤 | 8(2.41) | 1(0.87) | 0(0.00) | χ2=1.783 | 0.182 |
肺曲霉病 | 23(6.93) | 2(1.74) | 4(11.43) | χ2=7.016 | 0.030 |
抗菌药物 | 鸟分枝杆菌 (17株) | 胞内分枝杆菌 (159株) | 堪萨斯分枝杆菌 (16株) | 猿分枝杆菌 (2株) | 脓肿分枝杆菌 (57株) |
---|---|---|---|---|---|
克拉霉素 | 0(0.00) | 5(3.14) | 0(0.00) | 0(0/2) | 4(7.02) |
阿米卡星 | 0(0.00) | 11(6.92) | 0(0.00) | 0(0/2) | 1(1.75) |
利奈唑胺 | 4(23.53) | 21(13.21) | 0(0.00) | 2(2/2) | 25(43.86) |
莫西沙星 | 11(64.71) | 100(62.89) | 0(0.00) | 2(2/2) | 55(96.49) |
环丙沙星 | 17(100.00) | 158(99.37) | 7(43.75) | 2(2/2) | 57(100.00) |
多西环素 | 17(100.00) | 159(100.00) | 11(68.75) | 2(2/2) | 57(100.00) |
米诺环素 | 17(100.00) | 159(100.00) | 10(62.50) | 2(2/2) | 57(100.00) |
复方新诺明 | 17(100.00) | 159(100.00) | 14(87.50) | 2(2/2) | 57(100.00) |
利福平 | * | * | 0(0.00) | 1(1/2) | - |
利福布汀 | * | * | 0(0.00) | 1(1/2) | - |
头孢西丁 | - | - | - | - | 5(8.77) |
亚胺培南 | - | - | - | - | 52(91.23) |
妥布霉素 | - | - | - | - | 53(92.98) |
[1] | Falkinham JO 3rd. Ecology of Nontuberculous Mycobacteria. Microorganisms, 2021, 9(11):2262. doi:10.3390/microorganisms9112262. |
[2] | Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement:diagnosis,treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med, 2007, 175(4): 367-416. doi:10.1164/rccm.200604-571ST. |
[3] | 中华医学会结核病学分会. 非结核分枝杆菌病诊断与治疗指南(2020年版). 中华结核和呼吸杂志, 2020, 43(11):918-946. doi:10.3760/cma.j.cn112147-20200508-00570. |
[4] | 聂琦, 周勇, 陈华, 等. 非结核分枝杆菌病流行病学研究进展. 中华临床感染病杂志, 2020, 13(5):394-400. doi:10.3760/cma.j.issn.1674-2397.2020.05.014. |
[5] | 杨松, 王乐乐, 严晓峰, 等. 非结核分枝杆菌病治疗药物研究进展. 中华结核和呼吸杂志, 2021, 44(1): 44-49. doi:10.3760/cma.j.cn112147-20200227-00199. |
[6] | 段鸿飞. 及时掌握研究进展切实提高非结核分枝杆菌病治疗水平. 中国防痨杂志, 2023, 45(4):329-332. doi:10.19982/j.issn.1000-6621.20220515. |
[7] |
Hoefsloot W, van Ingen J, Andrejak C, et al. The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. Eur Respir J, 2013, 42(6): 1604-1613. doi:10.1183/09031936.00149212.
pmid: 23598956 |
[8] |
Tan YJ, Deng Y, Yan X, et al. Nontuberculous mycobacterial pulmonary disease and associated risk factors in China: A prospective surveillance study. J Infect, 2021, 83(1): 46-53. doi:10.1016/j.jinf.2021.05.019.
pmid: 34048821 |
[9] | Liu CF, Song YM, He WC, et al. Nontuberculous mycobacteria in China: incidence and antimicrobial resistance spectrum from a nationwide survey. Infect Dis Poverty, 2021, 10(1): 59. doi:10.1186/s40249-021-00844-1. |
[10] | 楼海, 孙勤, 顾瑾, 等. 常见非结核分枝杆菌肺病的临床特征及药物敏感试验结果分析. 中华结核和呼吸杂志, 2019, 42(12):901-906. doi:10.3760/cma.j.issn.1001-0939.2019.12.005. |
[11] | Uwamino Y, Nishimura T, Sato Y, et al. Low serum estradiol levels are related to Mycobacterium avium complex lung disease: a cross-sectional study. BMC Infect Dis, 2019, 19(1):1055. doi:10.1186/s12879-019-4668-x. |
[12] | Choi H, Han K, Yang B, et al. Female Reproductive Factors and Incidence of Nontuberculous Mycobacterial Pulmonary Disease Among Postmenopausal Women in Korea. Clin Infect Dis, 2022, 75(8):1397-1404. doi:10.1093/cid/ciac134. |
[13] | 严瑾瑜, 邹涛, 郭健, 等. 胞内分枝杆菌肺病与堪萨斯分枝杆菌肺病临床特征分析. 结核与肺部疾病杂志, 2021, 2(3):294-297. doi:10.3969/j.issn.2096-8493.20210049. |
[14] | Przybylski G, Nowakowska-Arendt A, Pilaczyńska-Ceme M, et al. 10 years comparative clinico-epidemiological analysis of smoking and alcohol consumption in TB patients (Myc.Tuberculosis) and with mycobacteriosis (Myc Kansas). Przegl Lek, 2014, 71(11):576-580. |
[15] | Eaton T, Falkinham JO 3rd, von Reyn CF. Recovery of Mycobacterium avium from Cigarettes. J Clin Microbiol, 1995, 33(10): 2757-2758. doi:10.1128/jcm.33.10.2757-2758.1995. |
[16] | 孙怡, 韩秀迪, 刘学东. 免疫衰老与炎症在肺部疾病中的研究进展. 中华结核和呼吸杂志, 2024, 47(2):178-182. doi:10.3760/cma.j.cn112147-20230902-00128. |
[17] | World Health Organization. Global tuberculosis report 2023. Geneva: World Health Organization, 2023. |
[18] |
Loebinger MR, Quint JK, van der Laan R, et al. Risk Factors for Nontuberculous Mycobacterial Pulmonary Disease: A Systematic Literature Review and Meta-Analysis. Chest, 2023, 164(5):1115-1124. doi:10.1016/j.chest.2023.06.014.
pmid: 37429481 |
[19] | 徐金富, 季晓彬, 范莉超, 等. 支气管扩张症患者合并非结核分枝杆菌肺部感染的临床分析. 中华结核和呼吸杂志, 2014, 37(4):301-302. doi:10.3760/cma.j.issn.1001-0939.2014.04.019. |
[20] | 李静, 郭乐, 白广红, 等. 2019—2021年陕西省结核病防治院患者的非结核分枝杆菌菌种分布特征及流行情况. 疾病监测, 2023, 38(9):1039-1042. doi:10.3784/jbjc.202302170048. |
[21] | Veyrier F, Pletzer D, Turenne C, et al. Phylogenetic detection of horizontal gene transfer during the step-wise genesis of Mycobacterium tuberculosis. BMC Evol Biol, 2009, 9:196. doi:10.1186/1471-2148-9-196. |
[22] | 黄畅宇, 戴爱国. 香烟烟雾对细胞生物学功能的影响. 国际呼吸杂志, 2012, 32(16):1278-1281. doi:10.3760/cma.j.issn.1673-436x.2012.016.019. |
[23] |
Mehta M, Chapman KR, Heffer M, et al. Impact of pulmonary nontuberculous mycobacterial treatment on pulmonary function tests in patients with and without established obstructive lung disease. Respirology, 2015, 20(6): 987-993. doi:10.1111/resp.12565.
pmid: 26011313 |
[24] | van Ingen J, Boeree MJ, van Soolingen D, et al. Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria. Drug Resist Updat, 2012, 15(3):149-161. doi:10.1016/j.drup.2012.04.001. |
[25] |
Zheng HW, Pang Y, He GX, et al. Comparing the genotype and drug susceptibilities between Mycobacterium avium and Mycobacterium intracellulare in China. Biomed Environ Sci, 2017, 30(7):517-525. doi:10.3967/bes2017.068.
pmid: 28756811 |
[26] | Johnston JC, Chiang L, Elwood K. Mycobacterium kansasii. Microbiol Spectr, 2017, 5(1). doi:10.1128/microbiolspec.TNMI7-0011-2016. |
[27] | 王洁莹, 陈灼霖, 许玉妮, 等. 海南省某医院2014—2021年脓肿拟分枝杆菌分离鉴定及药物敏感性分析. 中国热带医学, 2023, 23(9):947-953. doi:10.13604/j.cnki.46-1064/r.2023.09.10. |
[28] | Pang H, Li G, Zhao X, et al. Drug susceptibility testing of 31 antimicrobial agents on rapidly growing mycobacteria isolates from China. Biomed Res Int, 2015, 2015:419392. doi:10.1155/2015/419392. |
[1] | Hu Yifan, Du Boping, Wu Yadong, Zhu Chuanzhi, Zhang Lanyue, Jia Hongyan, Sun Qi, Pan Liping, Zhang Zongde, Li Zihui. Experimental study on the role of Mce4C in the uptake and utilization of cholesterol by Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 444-453. |
[2] | Sheng Jie, Hong Kaifeng, Mierzhati Aisha, Tang Wei, Dilixiati Abulizi. Study on the mechanism of IL-22 and p38 MAPK signaling pathways in inhibiting bone destruction in bone and joint tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 454-459. |
[3] | Wang Yingchao, Liu Weiyi, Ji Xiuxiu, Shang Xuetian, Jia Hongyan, Zhang Lanyue, Sun Qi, Du Boping, Zhu Chuanzhi, Pan Liping, Zhang Zongde. Profile analysis of circRNA expression and identification of diagnostic markers in peripheral blood mononuclear cells of tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 460-470. |
[4] | Hao Mingxiao, Mi Jie, Xu Zongyi. Effectiveness of a continuity of care model in patients with tuberculous meningitis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 477-481. |
[5] | Huang Misun, Wu Yaning, Li Guilian, Liu Haican. Research advances of Mycobacterium tuberculosis enrichment technology [J]. Chinese Journal of Antituberculosis, 2025, 47(3): 369-373. |
[6] | Li Qi, Wang Yujin, Wang Xueyu, Chu Naihui, Nie Wenjuan. Study on the metabolic interaction mechanism between the novel compound WX-081 and clarithromycin [J]. Chinese Journal of Antituberculosis, 2025, 47(2): 142-149. |
[7] | Zhang Chao, Yu Xia, Huang Hairong, Liu Wei, Liu Tao. Evaluation of the in vitro antimicrobial effects of sevoflurane on Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(2): 158-163. |
[8] | Liu Ruihua, Sarina , Wang Furong. Interaction between lung cancer and tuberculosis in disease development and progression [J]. Chinese Journal of Antituberculosis, 2025, 47(1): 102-111. |
[9] | Chen Jifei, Huang Lihua, Luo Lanbo, Sui Wenxian, Pang Yu, Liu Aimei. Evaluation the efficacy of tongue swab-based PCR fluorescence probe method for pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(1): 51-60. |
[10] | Zhao Yue, Wang Haoran, Cheng Meijin, Wang Wei, Liang Ruixia, Huang Hairong. The evaluation of the smear-positive and Xpert-negative outcome as an early indicator of nontuberculous mycobacteria existence in clinical specimen [J]. Chinese Journal of Antituberculosis, 2025, 47(1): 61-65. |
[11] | Lu Hailin, Wang Wenfei, Tao Wenhui, Lin Peicong, Chen Xinchun, Deng Guofang, Xie Shuixiang. Oleic acid upregulates the expression of perilipin 2 enhancing macrophage clearance of Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(1): 72-76. |
[12] | Fan Jun, Wang Heng, Lan Tinglong, Dong Weijie, Tang Kai, Li Yuan, Yan Guangxuan, Xu Shangsheng, Kang Zhigang, Qin Shibing. Clinical characteristics and surgical outcomes of 12 cases of non-tuberculous mycobacterial spondylitis [J]. Chinese Journal of Antituberculosis, 2025, 47(1): 87-95. |
[13] | Zhong Lingshan, Wang Li, Zhang Shuo, Li Nan, Yang Qingyuan, Ding Wenlong, Chen Xingzhi, Huang Chencui, Xing Zhiheng. A machine learning model based on CT images combined with radiomics and semantic features for diagnosis of nontuberculous mycobacterium lung disease and pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2024, 46(9): 1042-1049. |
[14] | Wang Yilin, Wu Xiao, Pang Yu, Li Shanshan. Immunomodulatory effect of orelabrutinib in host macrophages infected with mycobacterium [J]. Chinese Journal of Antituberculosis, 2024, 46(9): 1063-1068. |
[15] | Palidanguli Abudureheman, Wang Senlu, Gulina Badeerhan, Wang Le, Zulikatiayi Abudula, Wang Xinqi, Maiwulajiang Yimamu, Wang Xijiang. Distribution of Mycobacterium tuberculosis genotypes in Kashgar region and their association with clinical characteristics of pulmonary tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2024, 46(9): 1077-1082. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||